Related Experiment Videos
[Treatment of hepatitis C]
Vanessa Escuret1, Fabien Zoulim
1Inserm U271, 151, cours Albert Thomas, 69424 Lyon Cedex 03
La Revue Du Praticien
|May 26, 2005
Summary
Chronic hepatitis C treatment combines pegylated interferon alpha (PEG IFN) and ribavirin, achieving sustained virological response in most patients. Careful monitoring for adverse events and viral factors guides effective hepatitis C virus (HCV) therapy.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Context:
- Hepatitis C virus (HCV) infection affects 3% of the global population, posing a significant worldwide health challenge.
- Current standard treatment involves pegylated interferon alpha (PEG IFN) combined with ribavirin.
Purpose:
- To outline the efficacy and adverse events of current HCV treatments.
- To define treatment duration and monitoring strategies based on viral genotype and response.
- To identify factors influencing treatment outcomes and suggest future therapeutic directions.
Summary:
- Sustained virological response rates vary by HCV genotype (80% for genotypes 2/3, 50% for genotype 1).
- PEG IFN and ribavirin have distinct adverse event profiles (flu-like symptoms, psychiatric disorders, anemia) requiring close patient follow-up.
- Treatment duration and continuation decisions are guided by viral load monitoring (early virological response) and patient factors.
Impact:
- Optimizing current treatment protocols can improve sustained virological response rates in chronic hepatitis C patients.
- Understanding host and viral factors influencing treatment response is crucial for personalized medicine approaches.
- Research into novel therapeutic strategies combining PEG IFN with direct-acting antivirals holds promise for enhancing HCV eradication rates.